Recombinant TNFRSF8 (Brentuximab Biosimilar) 抗体
-
- 抗原 See all TNFRSF8 (Brentuximab Biosimilar) products
- TNFRSF8 (Brentuximab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Human
- Expression System
- CHO Cells
-
克隆类型
- 单克隆
-
标记
- This TNFRSF8 (Brentuximab Biosimilar) antibody is un-conjugated
- 应用范围
- ELISA, Surface Plasmon Resonance (SPR), Functional Studies (Func), Flow Cytometry (FACS), Bio-Layer Interferometry (BLI)
- 原理
- Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab)
- 序列
- QIQLQQSGPE VVKPGASVKI SCKASGYTFT DYYITWVKQK PGQGLEWIGW IYPGSGNTKY NEKFKGKATL TVDTSSSTAF MQLSSLTSED TAVYFCANYG NYWFAYWGQG TQVTVSAAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG,DIVLTQSPAS LAVSLGQRAT ISCKASQSVD FDGDSYMNWY QQKPGQPPKV LIYAASNLES GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCQQSNEDPW TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
- 产品特性
- Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.38 kDa.
- 纯度
- >95 %
- 亚型
- IgG1
-
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 说明
-
Therapeutic Agents by Target and Mechanism: CD30 inhibitors
Conditions: Anaplastic Large Cell Lymphoma Hematologic malignancies Hodgkin Lymphoma
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 浓度
- 1 mg/mL
- 缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- 储存条件
- 4 °C,-80 °C
- 储存方法
- +4°C,-80°C
-
- 抗原
- TNFRSF8 (Brentuximab Biosimilar)
- Abstract
- TNFRSF8 (Brentuximab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
- Synonyms: TNFRSF8
- 分子量
- 145.38 kDa
- UniProt
- P28908
-